[This retracts the article on p. 12113 in vol. 8, PMID: 26550123.].
[This retracts the article on p. 12113 in vol. 8, PMID: 26550123.].
The oncological outcomes of upper tract urothelial carcinoma (UTUC) and bladder cancer (BC) in patients treated with radical surgeries remains controversial. A retrospective analysis of the clinicopathologicla data of 228 consecutive UTUC patients and 174 BC patients treated with radical surgeries from 2000 to 2012 at a high-volume center in China was conducted. Kaplan-Meier method and Cox regression were used to compare overall survival (OS) and cancer-specific survival (CSS) and to find prognostic factors. In this cohort of patients, BC were associated with male sex (P<0.001), multifocality (P<0.001), positive lymph node (P=0.002), no hydronephrosis (P<0.001) and open surgical approach (P<0.001). UTUC have statistically significant better 5-year CSS rate (61.0% vs. 49.8%, P=0.008) and OS rate (58.3% vs. 37.4%, P<0.001) than BC. Bladder tumor location (UTCU vs. BC: hazard ratio (HR)=0.703 and HR=0.462) and positive lymph node status (HR=1.919 and HR=1.667) were independent risk factors of cancer-specific death and overall mortality, respectively. Our data suggest that locally invasive urothelial carcinomas (UC) behave differently in the upper and lower urinary tracts. UTUC has a better prognosis than BC when stage and grade are considered simultaneously and lymph node involvement has significant influences on clinical outcomes of urothelial carcinoma.
[This retracts the article on p. 4131 in vol. 7, PMID: 25550923.].
[This retracts the article on p. 16969 in vol. 8, PMID: 26629252.].
[This retracts the article on p. 10603 in vol. 8, PMID: 26379850.].
[This retracts the article on p. 2334 in vol. 8, PMID: 25932170.].
[This retracts the article on p. 3338 in vol. 8, PMID: 26064224.].
[This retracts the article on p. 14944 in vol. 8, PMID: 26628976.].
PSMD10, also known as gankyrin, is associated with the proteasome and has been shown to be an oncoprotein in the liver. Here, we report that PSMD10 expression is stimulated by the histone demethylase JMJD2A/KDM4A and its interaction partner, the ETV1 transcription factor, in LNCaP prostate cancer cells. Global analysis of expression patterns revealed that PSMD10 mRNA levels are positively correlated with those of both JMJD2A and ETV1. In human prostate tumors, PSMD10 is highly overexpressed at the protein level and correlates with JMJD2A overexpression; further, PSMD10 expression is enhanced in the prostates of transgenic JMJD2A mice. Moreover, PSMD10 is particularly overexpressed in high Gleason score prostate tumors. Downregulation of PSMD10 in LNCaP prostate cancer cells impaired their growth, indicating that PSMD10 may exert a pro-oncogenic function in the prostate. Lastly, we observed that PSMD10 expression is correlated to YAP1, a component of the Hippo signaling pathway and whose gene promoter is regulated by JMJD2A, and that PSMD10 can cooperate with YAP1 in stimulating LNCaP cell growth. Altogether, these data indicate that PSMD10 is a novel downstream effector of JMJD2A and suggest that inhibition of the JMJD2A histone demethylase by small molecule drugs may be effective to curtail the oncogenic activity of PSMD10 in various PSMD10-overexpressing tumors.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：